Novo Nordisk slumps following trial results for Eli Lilly’s weight-loss pill

Novo Nordisk slumps following trial results for Eli Lilly’s weight-loss pill

Novo Nordisk fell almost 10% early on Tuesday....

Rival fat-loss pill wipes billions off Novo Nordisk

Billions were wiped off the value of Ozempic-maker Novo Nordisk yesterday after a promising drug trial by a US rival, writes Emily Hawkins. The Danish pharma giant’s shares fell by up to 9pc yesterday, the first trading day since Eli Lilly announced that its experimental daily pill may work just as well as fat jabs. Although the group clung on to its title as Europe’s second largest company, it shed €11bn as shares closed down 7.4pc, leaving it …

The company has explained that this pill helps patients with type 2 diabetes to reduce their blood sugar and body weight, showing a "comparable safety" with popular injections on the market. According to some analysts, this pill, more convenient and easy to manufacture, could give Eli Lilly an important advantage over Novo Nordisk and other competitors trying to enter the lucrative weight loss drug sector.

Novo Nordisk shares fell by more than seven percent today.

16:30 Danish pharmaceutical company Novo Nordisk fell on the Copenhagen stock exchange on Tuesday after its US rival Eli Lilly scored with a candidate obesity pill, the holy grail in the field.

The share price of the Danish pharmaceutical company Novo Nordisk, which had been successful with weight loss injections, collapsed on Tuesday. This is the reason for a successful clinical test of a weight loss pill by US competitor Eli Lilly. Novo Nordisk also announced a weight loss pill - in this form the drug is not only easier to take, the tablet is reported to be significantly cheaper than a syringe. Novo Nordisk's price on the Copenhagen …